AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the rapidly-spreading Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an ...

An illustration picture shows vials with Covid-19 vaccine stickers attached and syringes, with the logo of the University of Oxford and its partner British pharmaceutical company AstraZeneca.

The University of Oxford's and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries ...

Why the AstraZeneca-Oxford Covid-19 vaccine is different AstraZeneca and the University of Oxford say their vaccine has up to 90 percent efficacy. But there’s a lot we still don’t know.

The University of Oxford has suspended AstraZeneca COVID-19 vaccinations in a small clinical trial for children, while the U.K.’s medicines regulator examines reports of rare blood clotting in ...

AstraZeneca said in an emailed statement that its own data of more than 10 million patient records showed the incidence of blood clots was actually lower than the general population's rate.

(Reuters) - AstraZeneca and Oxford University's COVID-19 vaccine is more effective when its second dose is given three months after the first, instead of six weeks, a peer-reviewed study published ...

The AstraZeneca/Oxford vaccine is an adenovirus-vectored vaccine, meaning that it uses a harmless version of the common cold virus that has been modified to be both weak and also contain a gene ...

The World Health Organization approved the AstraZeneca/Oxford Covid-19 vaccine for emergency use Monday, which could help developing countries access the vaccine and make it easier for other ...

Britain's University of Oxford said Saturday it will test its Covid-19 vaccine in children for the first time, to assess whether it is effective in the young.

South Africa halted the rollout of the AstraZeneca-Oxford COVID-19 vaccine this week after a trial showed it did not prevent mild and moderate disease. Data on this vaccine has been confusing.